用自然获得的免疫反应来开发单克隆抗体的SARS-CoV-2尖端蛋白的皮质映射
Rubén López-Aladid1,2, Leticia Bueno-Freire3,4, Roc Farriol-Duran5,6
1Cellex Laboratory, Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (CIBERES, 06/06/0028), Fundació de Recerca Clínic Barcelona-Institut d'Investigacions Biomèdiques August Pi i Sunyer (FRCB-IDIBAPS), School of Medicine, Universitat de Barcelona, Barcelona, Spain. ruben.aladid@gmail.com.
Scientific reports
|May 9, 2025
概括
研究人员在SARS-CoV-2尖端蛋白上确定了高度反应的B细胞表位,用于潜在的COVID-19疗法. 这种计算和实验方法产生了有前途的单克隆抗体治疗,特别是对于那些没有完全响应疫苗的人.
科学领域:
- 免疫学 免疫学 免疫学
- 病毒学 病毒学
- 计算生物学 计算生物学
背景情况:
- 虽然COVID-19疫苗接种广泛,但对于免疫力低下等弱势群体需要治疗替代方案.
- 开发新的治疗方法对于那些免疫反应不佳的人来说至关重要.
研究的目的:
- 通过计算预测和实验验证SARS-CoV-2尖端蛋白质上的免疫B细胞表位.
- 确定用于开发治疗性单克隆抗体的表位对抗COVID-19.
主要方法:
- 使用Brewpitopes管道 (BepiPred v2.0,Discotope v2.0) 与可访问性过器进行25个B细胞表位的in silico预测.
- 使用多重免疫试验从509名COVID-19康复患者的血清/血中选预测的表位.
- 产生和特征单克隆抗体对抗最免疫原性表位.
主要成果:
- 在25个预测的SARS-CoV-2尖端蛋白表位中,有3个在康复患者样本中显示出显著更高的IgG反应性.
- 对这些顶部表位的血清阳性在患者队列中从11%到48%不等.
- 成功生成了两种单克隆抗体,证明了与现有的商业抗体相比,S蛋白相似的亲和力.
结论:
- 在 silico 预测管道成功识别了由患者 IgG 识别的免疫原性 SARS-CoV-2 尖端蛋白质表位.
- 这些经过验证的表位体适合开发用于预防和治疗COVID-19的基于抗体的新疗法.
- 这些发现支持使用计算表位图绘制来快速开发医疗对策.
相关概念视频
Conjugated Proteins
18.1K
Simple proteins and protein complexes contain only amino acids. In contrast, many other proteins, called conjugated proteins, covalently bond with non-protein moieties.
Nucleoproteins are protein complexes that contain nucleic acids, categorized as deoxyribonucleoproteins (DNPs) or ribonucleoproteins (RNPs) respectively. The nucleosome is a typical example of a DNP where nuclear DNA is associated with histone proteins. The major antigen for the Covid-19 virus SARS-CoV is an RNP that is critical...
Nucleoproteins are protein complexes that contain nucleic acids, categorized as deoxyribonucleoproteins (DNPs) or ribonucleoproteins (RNPs) respectively. The nucleosome is a typical example of a DNP where nuclear DNA is associated with histone proteins. The major antigen for the Covid-19 virus SARS-CoV is an RNP that is critical...
18.1K
Cross-reactivity
30.9K
Overview
30.9K
Hybridoma Technology
13.8K
Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
13.8K


